These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12890531)

  • 41. HER1/EGFR targeting: refining the strategy.
    Pérez-Soler R
    Oncologist; 2004; 9(1):58-67. PubMed ID: 14755015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabotropic glutamate receptor 5-induced phosphorylation of extracellular signal-regulated kinase in astrocytes depends on transactivation of the epidermal growth factor receptor.
    Peavy RD; Chang MS; Sanders-Bush E; Conn PJ
    J Neurosci; 2001 Dec; 21(24):9619-28. PubMed ID: 11739572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advanced glycation end product precursors impair epidermal growth factor receptor signaling.
    Portero-Otín M; Pamplona R; Bellmunt MJ; Ruiz MC; Prat J; Salvayre R; Nègre-Salvayre A
    Diabetes; 2002 May; 51(5):1535-42. PubMed ID: 11978653
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.
    Lackey KE
    Curr Top Med Chem; 2006; 6(5):435-60. PubMed ID: 16719802
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A pH sensitive colorometric assay for the high-throughput screening of enzyme inhibitors and substrates: a case study using kinases.
    Chapman E; Wong CH
    Bioorg Med Chem; 2002 Mar; 10(3):551-5. PubMed ID: 11814841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.
    Huang KY; Kao SH; Wang WL; Chen CY; Hsiao TH; Salunke SB; Chen JJ; Su KY; Yang SC; Hong TM; Chen CS; Yang PC
    Am J Respir Crit Care Med; 2016 Apr; 193(7):753-66. PubMed ID: 26583948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.
    Ménard L; Floc'h N; Martin MJ; Cross DAE
    Cancer Res; 2018 Jun; 78(12):3267-3279. PubMed ID: 29555874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Abstracts of the 3rd International Conference on Inhibitors of Protein Kinases, June 22-27, 2003 and Workshop on Phosphoryl-Transfer Mechanisms, June 27-29, 2003. Warsaw, Poland.
    Cell Mol Biol Lett; 2003; 8(2A):503-631. PubMed ID: 12813492
    [No Abstract]   [Full Text] [Related]  

  • 51. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.
    Fry DW
    Pharmacol Ther; 1999; 82(2-3):207-18. PubMed ID: 10454198
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis.
    Angiolini M
    Future Med Chem; 2011 Mar; 3(3):309-37. PubMed ID: 21446845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer.
    Kondapaka BS; Reddy KB
    Mol Cell Endocrinol; 1996 Mar; 117(1):53-8. PubMed ID: 8734473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer.
    Krähn G; Leiter U; Kaskel P; Udart M; Utikal J; Bezold G; Peter RU
    Eur J Cancer; 2001 Jan; 37(2):251-9. PubMed ID: 11166154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted therapies in gynecologic cancers.
    Chon HS; Hu W; Kavanagh JJ
    Curr Cancer Drug Targets; 2006 Jun; 6(4):333-63. PubMed ID: 16848724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Issues and progress with protein kinase inhibitors for cancer treatment.
    Dancey J; Sausville EA
    Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
    Wang X; Xu L; Lao Y; Zhang H; Xu H
    Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling.
    Weng MS; Ho CT; Ho YS; Lin JK
    Toxicol Appl Pharmacol; 2007 Jan; 218(2):107-18. PubMed ID: 17182072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of calmodulin in the modulation of the MAPK signalling pathway and the transactivation of epidermal growth factor receptor mediated by PKC.
    Tebar F; Lladó A; Enrich C
    FEBS Lett; 2002 Apr; 517(1-3):206-10. PubMed ID: 12062438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.